Kura Investors

Investor Home

Corporate Profile
We are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. Our development programs target cancers with high unmet need, including head and neck, lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias.
Recent Newsmore >
Kura Oncology Added to Russell 3000® Index
Kura Oncology Presents Preliminary Clinical and Preclinical Data for Tipifarnib in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
Kura Oncology Announces Data Presentations for Tipifarnib at the International Conference on Malignant Lymphoma and the European Hematology Association Annual Meeting
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Kura Oncology Inc posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.